Biovie is trading 25.38% up at $2.33 after renewed investor attention to positive Phase 2 SUNRISE-PD results for bezisterim in early Parkinson’s disease.
- The trial reported statistically significant clinical and biomarker improvements versus placebo, including motor and non-motor measures.
- Bezisterim maintained a placebo-like safety profile, supporting expectations for further development.
- Biovie gained 38.81% on August 20 and 38.95% on August 19, indicating sustained momentum around the clinical update.